Disease: melanoma ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0025202
Disease: melanoma
melanoma 		0.700 CausalMutation disease CLINVAR Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. 22588879 2012
CUI: C0025202
Disease: melanoma
melanoma 		0.700 Biomarker disease BEFREE The mitogen-activated extracellular signal-regulated kinase 1/2 (MEK1/2) inhibitor trametinib has shown promising therapeutic effects on melanoma, but its efficacy on colorectal cancer (CRC) is limited. 28756770 2017
CUI: C0025202
Disease: melanoma
melanoma 		0.700 CausalMutation disease CLINVAR Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. 21383288 2011
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease BEFREE In patients with BRAF-mutated melanoma specific inhibitors of BRAF<sup>V600E</sup> and MEK1/2 frequently induce initial tumor reduction, frequently followed by relapse. 28720543 2017
CUI: C0025202
Disease: melanoma
melanoma 		0.700 Biomarker disease BEFREE While the role of the BRAF-MEK1/2-ERK1/2 pathway in melanoma is well established, the involvement of mitogen-activated protein kinases MEK5-ERK5 remains poorly explored. 29483645 2018
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease BEFREE Cobimetinib: inhibiting MEK1/2 in BRAF V600-mutant melanoma. 28112278 2016
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease CLINVAR Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. 23444215 2013
CUI: C0025202
Disease: melanoma
melanoma 		0.700 Biomarker disease BEFREE Furthermore, recently identified ERK1/2-inducing mutations in MEK1 and MEK2 (MEK1/2) MAPK genes in melanoma confer resistance to emerging therapeutic MEK inhibitors, underscoring the challenges facing direct kinase inhibition in cancer. 23603816 2013
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease BEFREE Screening a larger cohort of individuals with melanoma revealed the presence of recurring somatic MAP2K1 and MAP2K2 mutations, which occurred at an overall frequency of 8%. 22197931 2011
CUI: C0025202
Disease: melanoma
melanoma 		0.700 Biomarker disease CTD_human Screening a larger cohort of individuals with melanoma revealed the presence of recurring somatic MAP2K1 and MAP2K2 mutations, which occurred at an overall frequency of 8%. 22197931 2011
CUI: C0025202
Disease: melanoma
melanoma 		0.700 Biomarker disease BEFREE FABP7 mRNA and protein level is down-regulated following treatment of melanoma cell lines with a PKC activator (PMA) or MEK1 inhibitor (PD98059). 18826602 2008
CUI: C0025202
Disease: melanoma
melanoma 		0.700 Biomarker disease BEFREE BRAF and MEK1/2 inhibitors are effective in melanoma but resistance inevitably develops. 31727888 2019
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease BEFREE Combinatorial inhibition of MEK1/2 and CDK4/6 is currently undergoing clinical investigation in NRAS-mutant melanoma. 30819666 2019
CUI: C0025202
Disease: melanoma
melanoma 		0.700 Biomarker disease BEFREE Coupling MEK1/2 inhibitors with B-Raf inhibitors is more effective in treating such melanomas and dual therapy is now the standard of care. 30118796 2018
CUI: C0025202
Disease: melanoma
melanoma 		0.700 AlteredExpression disease BEFREE Anthrax lethal toxin-sensitive melanoma cell lines and normal cells had higher phospho-MEK1/2 levels than anthrax lethal toxin-resistant melanoma cell lines and normal tissue types. 16170021 2005
CUI: C0025202
Disease: melanoma
melanoma 		0.700 Biomarker disease BEFREE It inhibited colorectal cancer and melanoma cell proliferation much more effectively than its negative control MS432N (<b>24</b>), and its effect was phenocopied by MEK1/2 knockdown. 31730343 2019
CUI: C0025202
Disease: melanoma
melanoma 		0.700 Biomarker disease BEFREE A MEK1/2 inhibitor, binimetinib is promising as a therapeutic agent for malignant melanoma with N-RAS mutation. 31129802 2019
CUI: C0025202
Disease: melanoma
melanoma 		0.700 AlteredExpression disease LHGDN Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway. 12917419 2003
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease CLINVAR Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. 23569304 2013
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease BEFREE Taken together, our data indicate that preexisting MEK1(P124) mutations are associated with a reduced response to BRAF inhibitor therapy and identify a subset of patients with BRAF-mutant melanoma likely to benefit from combination therapies involving MEK or ERK inhibitors. 25370473 2015
CUI: C0025202
Disease: melanoma
melanoma 		0.700 CausalMutation disease CLINVAR COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. 21107320 2010
CUI: C0025202
Disease: melanoma
melanoma 		0.700 Biomarker disease BEFREE Furthermore, we found that melanoma cell integrin alphav was required for MAPK kinase (MEK) 1 and extracellular signal-regulated kinase (ERK)1/2 activity in 3D-collagen, whereas inhibition of MEK1 activity induced apoptosis. 15557124 2004
CUI: C0025202
Disease: melanoma
melanoma 		0.700 GeneticVariation disease BEFREE Thus, activating MEK1 exon 3 mutations identified herein and concurrent with V600E/KBRAF do not cause BRAFi resistance in melanoma. 22588879 2012
CUI: C0025202
Disease: melanoma
melanoma 		0.700 CausalMutation disease CLINVAR Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model. 24448821 2014
CUI: C0025202
Disease: melanoma
melanoma 		0.700 Biomarker disease BEFREE Targeting BMK1 Impairs the Drug Resistance to Combined Inhibition of BRAF and MEK1/2 in Melanoma. 28387310 2017